Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

The DESKTOP III Trial with Philipp Harter

The DESKTOP III Trial with Philipp Harter

FromIJGC Podcast


The DESKTOP III Trial with Philipp Harter

FromIJGC Podcast

ratings:
Length:
41 minutes
Released:
Jan 24, 2022
Format:
Podcast episode

Description

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Prof. Philipp Harter to discuss The DESKTOP III Trial. Prof. Harter is the director of the Department of Gynecology & Gynecologic Oncology at Kliniken Essen-Mitte in Essen, Germany, and the chair of the AGO Study Group.
Highlights:
-Role of surgery for relapsed ovarian cancer is under debate
-DESKTOP III has shown a significant benefit regarding PFS and OS by secondary cytoreduction
-The data, interpretation and clinical consequences are discussed".
Released:
Jan 24, 2022
Format:
Podcast episode

Titles in the series (100)

From June 2023, all our podcasts will move to https://ijgcbmj.podbean.com. You can continue with your subscription on your favourite podcast App. The International Journal of Gynecological Cancer publishes content on novel and relevant topics in the field of gynecologic cancer. IJGC Podcast features short interview segments with leading experts discussing the latest research in their respective areas. The podcasts will serve as an interactive and education experience for all our listeners. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.